Biochemistry and Biophysics Reports (Dec 2022)

Therapeutic strategy for facial paralysis based on the combined application of Si-based agent and methylcobalamin

  • Yoshihisa Koyama,
  • Shotaro Harada,
  • Takashi Sato,
  • Yuki Kobayashi,
  • Hiroto Yanagawa,
  • Toru Iwahashi,
  • Hiroyuki Tanaka,
  • Kazuya Ohata,
  • Takao Imai,
  • Yumi Ohta,
  • Takefumi Kamakura,
  • Hikaru Kobayashi,
  • Hidenori Inohara,
  • Shoichi Shimada

Journal volume & issue
Vol. 32
p. 101388

Abstract

Read online

Facial paralysis results in the decline in the generation of facial expressions and is attributed to several causes. Intractable facial paralysis has a poor prognosis, and new treatments are required. Facial paralysis results in the decline in the generation of facial expressions and is attributed to several causes. Reactive oxygen species can inhibit peripheral nerve regeneration after injury. Therefore, the administration of an appropriate antioxidant can promote nerve regeneration. Silicon (Si)-based agents can react with water to generate antioxidant hydrogen. Oral administration of Si-based agents can effectively alleviate symptoms of disease models associated with oxidative stress. Thus, we orally administered a Si-based agent to a facial paralysis model mice to investigate whether promotion of nerve regeneration occurred. The combined administration of methylcobalamin (MeCbl) with the Si-based agent was also investigated. The Si-based agent improved the clinical score evaluation of facial paralysis. Electroneuronography and immunostaining showed that the Si-based agent promoted myelination and recovery of facial nerve function. Furthermore, in the drug-administered group, oxidative stress associated with facial nerve injury was reduced more than that in the non-administered group. The clinical score evaluation, neuroregeneration effect, and reduction of oxidative stress were improved in the combination group compared to the single administration group. The Si-based agent could rapidly improve the disappearance of facial expressions by promoting myelin sheath formation and alleviating oxidative stress. Combination therapy with a Si-based agent and MeCbl should improve the prognosis and treatment of intractable facial paralysis.

Keywords